Efficacy of the Topical Calcineurin Inhibitors Tacrolimus and Pimecrolimus in the Treatment of Vitiligo in Infants Under 2 Years of Age: A Randomized, Open-Label Pilot Study
ConclusionsTopical tacrolimus ointment 0.03% or pimecrolimus cream 1% have efficacy for vitiligo in infants, which serves to achieve an appropriate level of safety and tolerability during the 6-month period of applications. Thus, TCIs proved to be a therapeutic option for vitiligo in infants under 2 years of age.
In this study, the mean level of ZAG was found to be significantly lower in the vitiligo patients' tissue in comparison with the healthy control subjects' tissue ( p=0.001); the level of ZAG was also lower in vitiligo patients' serum in comparison with the healthy control subjects' serum ( p=0.001). A highly significant correlation was observed between the duration of the disease and the level of ZAG in the tissue of patients (r =0.9; p=0.001). Also a highly significant positive correlation was observed between the age of patients and the level of ZAG in the tissue (r =0.5; p=0.006). Diminishing...
ConclusionsThis study provided an overall picture of ICI-induced vitiligo in daily medical practice on a large number of pharmacovigilance observations of case patients. Among the observations of ICI-induced vitiligo, the diagnosed cancer was melanoma for almost all patients. Most patients in the study experienced other associated adverse drug reactions (ADRs), such as colitis, pruritus, hypothyroidism, hyperthyroidism, thyroiditis, pancreatitis, and gastritis. Furthermore, our data suggest that the resolution of pembrolizumab- or nivolumab-induced vitiligo could be a marker of disease progression. Future studies evaluatin...
This article provides clinicians with the critical information needed to safely and effectively provide phototherapy for their patients with vitiligo.
Conclusions: There is a significant immune-dysregulation with a preponderance of circulatory Th1/Th17 phenotype in NSV patients. PMID: 31616220 [PubMed]
;ez J PMID: 31621895 [PubMed - as supplied by publisher]
AbstractVitiligo is a skin disorder with melanocyte destruction and an autoimmune basis. Given the importance of cytokines in autoimmunity, we aimed to find the cytokine profile of innate and adaptive immunity in vitiligo patients, and correlate them with clinical parameters. The serum levels of innate immunity [interleukin(IL)-1 α, IL-1β, IL-6, IL-8, IL-12, IL-15 and tumor necrosis factor (TNF)-α] and T helper(Th)1 [IL-2, interferon (IFN)-γ, TNF-β], Th2 (IL-4, IL-5, IL-10, IL-13) and Th17 (IL-17, IL-23) cytokines in 44 vitiligo patients were measured by multiplex cytokine assay and compared wit...
PMID: 31621061 [PubMed - as supplied by publisher]
ConclusionsEvidence on the efficacy and safety of drugs targeting the JAK/STAT pathway for the treatment of patients with AD, vitiligo, or AA is increasing but is still of low quality.
Abstract Treatment options for vitiligo are limited and many cases remain refractory to first and second line treatments. Interferon-gamma signaling mediated by Janus kinase (JAK) has been implicated in the pathogenesis of vitiligo.1 Systemic administration of tofacitinib, a potent JAK1/3 inhibitor, has been effective in treating vitiligo in case reports,2 however, it is associated with infections, malignancies, cytopenias, gastrointestinal perforations, and hyperlipidemia in some patients with rheumatoid arthritis. PMID: 31605536 [PubMed - as supplied by publisher]
Balachandra S Ankad, Balakrishna P Nikam, Priyanka S JajuIndian Journal of Dermatology, Venereology, and Leprology 2019 85(6):634-637